Novel oncology therapies that leverage the changes in the DNA Damage Response (DDR) in cancer cells.

www.artiospharma.com

Sector

Therapeutics

Source

Other

Investment stage

Series A

Artios Pharma is developing novel oncology therapies that leverage the changes in the DNA Damage Response (DDR) in cancer cells.

In cancers, modifications to DDR pathways allow mutations in DNA to persist, leading to quicker adaptation and resistance to therapies. Targeting these pathways has been proven to selectively kill cancer cells through a concept known as ‘synthetic lethality’.

Artios was formed with assets out of Cancer Research Technology (CRT), the technology transfer unit of Cancer Research UK (CRUK), and has received investment from SV Life Sciences, Merck Ventures, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures, in addition to Innovations.

Related news

View all news